Included studies Sex (man/woman) (E/C) Age (E/C) (E/C)Experiment group intervention Control group intervention Outcomes Child-Pugh A/B/C ( ) Qi et al., 2003 [13 ] 28/6 24/6 32~68 36~72 34/30 As2 O3 (20 mg/d, qd) + TACE TACE (5-Fu 1 g + MMC 10 mg + Epi-ADM 60 mg + iodised oil 10–30 mL, iv, 35 days) Clinical effect, AFP, survival E: 28/4/2 C: 22/4/4 Cui et al., 2006 [7 ] 21/5 25/4 39~65 37~67 26/29 As2 O3 (20 mg/d, qd) + TACE TACE (MMC 6 mg/m2 + Epi-ADM 40 mg/m2 + iodised oil 10–30 mL, iv, 35 days) Clinical effect, AFP, survival E: NR C: NR Zhuang et al., 2006 [10 ] 44/18 36/20 26~76 24~79 62/56 As2 O3 (20 mg/d, qd) + TACE TACE (cisplatin 50 mg + MMC 10 mg + Epi-ADM 50 mg + iodised oil 10–30 mL, iv, 60 days) Clinical effect, AFP, survival E: 28/32/2 C: 25/28/3 Xie et al., 2007 [14 ] 25/8 23/9 21~70 21~70 33/32 As2 O3 (20 mg/d, qd) + TACE TACE (HCP 20 mg + ADM 50 mg + cisplatin 60 mg + iodised oil 5–20 mL, iv, 42 days) Clinical effect, AFP, survival, quality of life E: NR C: NR Zhou et al., 2007 [15 ] 35/6 40/5 21~75 23~74 41/45 As2 O3 (20 mg/d, qd) + TACE TACE (5-FU 750 mg + CAP 300 mg + THP 60 mg + iodised oil 2–5 mL, iv, 28 days) Clinical effect, AFP E: 35/6/0 C: 37/8/0 Wang, 2012 [5 ] 26/4 25/5 44~64 47~67 30/30 As2 O3 (20 mg/d, qd) + TACE TACE (CAP 300 mg + MMC 10 mg + iodised oil 5–20 mL, iv, 28 days) Clinical effect, AFP, quality of life E: NR C: NR Kui et al., 2010 [11 ] Unclear Unclear 16/15 As2 O3 (20 mg/d, qd) + TACE TACE (5-Fu 750 mg/m2 + cisplatin 60 mg + THP 20 mg/m2 , iv, 14 days) Clinical effect, survival E: NR C: NR Huang, 2011 [4 ] 13/2 11/4 48~68 45~71 15/15 As2 O3 (10 mg/d, qd) + TACE TACE (THP 20–40 mg + 5-Fu 500–750 mg + iodised oil, iv, 28 days) Clinical effect, survival E: NR C: NR Zhang et al., 2011 [12 ] 24/6 25/5 28~72 31~68 30/30 As2 O3 (20 mg/d, qd) + TACE TACE (CAP 300 mg + MMC 10 mg + iodised oil 5–20 mL, iv, 42 days) Clinical effect, quality of life E: NR C: NR Meng et al., 2012 [8 ] 22/8 19/11 36~77 23~78 30/30 As2 O3 (10 mg/d, qd) + TACE TACE (ADM 20–30 mg + capobenic 100–300 mg + iodised oil 6–20 mL, iv, 56 days) Clinical effect, quality of life E: NR C: NR Xing, 2012 [9 ] 18/5 23/2 44~66 46~64 23/25 As2 O3 (20 mg/d, qd) + TACE TACE (Epi-ADM 40 mg + saline 2 mL + iodised oil, iv, 28 days) Clinical effect, survival E: NR C: NR Hu et al., 2014 [16 ] 21/7 17/8 31~80 28~70 28/25 As2 O3 (10–20 mg/d, qd) + TACE TACE (oxaliplatin 150 mg + 5-FU 1.5 g + Epi-ADM 50 mg + iodised oil 10–20 mL, iv, above 28 days) Clinical effect, AFP, survival, quality of life E: NR C: NR Qian, 2014 [17 ] 32/8 35/5 33~81 31~68 40/40 As2 O3 (20 mg/d, qd) + TACE TACE (lobaplatin 20 mg + Epi-ADM 40 mg, iv, 28 days) Clinical effect, AFP, quality of life E: NR C: NR Wan et al., 2014 [18 ] 16/9 18/7 44~66 42~64 25/25 As2 O3 (10 mg/d, qd) + TACE TACE (Epi-ADM 40 mg/m2 + 5-Fu 1000 mg/m2 + cis-platinum 50 mg/m2 + iodised oil 5–20 mL, iv, above 28 days) Clinical effect, AFP, quality of life E: NR C: NR Xiang, 2014 [19 ] 22/5 25/3 49~71 47~69 27/28 As2 O3 (15 mg/d, qd) + TACE TACE (THP 20 mg + MMC 10 mg + iodised oil, iv, above 28 days) Clinical effect, AFP, survival, quality of life E: 24/3 C: 24/4 Meng et al., 2015 [20 ] 27/3 26/4 36~76 36~72 30/30 As2 O3 (10 mg/d, qd) + TACE TACE (oxaliplatin 100 mg + ADM 20–30 mg + iodised oil 3–15 mL, iv, 14 days) Clinical effect, quality of life E: NR C: NR Yang and Li, 2015 [21 ] 21/19 22/18 57~62 59~64 40/40 As2 O3 (10 mg/d, qd) + TACE TACE (ADM 20–40 mg/m2 + cis-platinum 20–40 mg/m2 + iodised oil, iv, 28 days) Clinical effect, AFP, survival E: NR C: NR